The latest myeloma news
ASH 2024: Daratumumab cuts risk of progression by half in smouldering multiple myeloma
Patients at high risk for developing multiple myeloma who received the drug daratumumab for up…
Browsing: Myeloma
ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for the Blenrep (belantamab mandolin) combination versus the…
ASH 2024: Resistance training can reduce fatigue, pain in multiple myeloma patients
Researchers from Roswell Park Comprehensive Cancer Center, USA, presented compelling findings showcasing the significant benefits…
ASH 2024: High-fibre diet may slow disease progression in multiple myeloma
New data suggest that a plant-based diet rich in fibre could help to improve the…
ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or refractory multiple myeloma
Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel…
A new technique that makes competition between tumour cells visible can help personalise treatments for multiple myeloma
All cells within the same cancer are not the same. They all have genetic errors…
An epigenetic characteristic help predict efficacy of immunotherapy in multiple myeloma
Multiple myeloma is a type of blood cancer that appears mainly after the age of…
FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC)…
‘Needless lives are being lost’ as charity reveals blood cancer survival in the UK is overshadowed by that in other countries
During Blood Cancer Awareness Month Blood Cancer UK releases its comprehensive Action Plan “Taking blood…
Unlocking the potential of targeted therapies for multiple myeloma
Multiple myeloma (MM) is a complex haematological malignancy with significant unmet needs. While conventional therapies…